Skip to main content

ORIGINAL RESEARCH article

Front. Endocrinol.
Sec. Clinical Diabetes
Volume 15 - 2024 | doi: 10.3389/fendo.2024.1374496
This article is part of the Research Topic Continuous Glucose Monitoring: Beyond Diabetes Management View all 3 articles

Accuracy of a novel real-time continuous glucose monitoring system: a prospective self-controlled study in thirty hospitalized patients with type 2 diabetes

Provisionally accepted
Shenghui Ge Shenghui Ge 1Hui Zhang Hui Zhang 2Jin Wang Jin Wang 3惠琴 李 惠琴 李 1Xiaofei Su Xiaofei Su 1Dafa Ding Dafa Ding 4*Jianhua Ma Jianhua Ma 1*
  • 1 Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University,, Nanjing, Liaoning Province, China
  • 2 Department of Endocrinology, Nanjing Tongren Hospital, School of Medicine, Southeast University, Nanjing, China
  • 3 Department of Health Management Center, Nanjing First Hospital, Nanjing Medical University, Nanjing, China, Nanjing, China
  • 4 Department of Endocrinology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China, Nanjing, China

The final, formatted version of the article will be published soon.

    Aims: The present study aimed to investigate the accuracy of the Glunovo® real-time continuous glucose monitoring system (rtCGMS). Methods: We conducted a 14-day interstitial glucose level monitoring using Glunovo® rtCGMS on thirty hospitalized patients with type 2 diabetes. The flash glucose monitoring (FGM) was used as a self-control. Consistency tests, error grid analysis, and calculation of the mean absolute relative difference (MARD) were performed using R software to assess the accuracy of Glunovo® rtCGMS. Results: Glunovo® exhibited an overall MARD value of 8.89% during hospitalization, compared to 10.42% for FGM. The overall percentages of glucose values within ±10%/10, ±15%/15, ±20%/20, ±30%/30, and ±40%/40 of the venous blood glucose reference value were 63.34%, 81.31%, 90.50%, 97.29%, and 99.36% for Glunovo®, respectively, compared with 61.58%, 79.63%, 88.31%, 96.22% and 99.23% for FGM. The Clarke Error Grid Analysis showed that 99.61% of Glunovo® glucose pairs and 100.00% of FGM glucose pairs within zones A and B. Conclusion: Our study confirms the superior accuracy of Glunovo® in monitoring blood glucose levels among hospitalized patients with type 2 diabetes.

    Keywords: Glunovo®, rtCGMS, type 2 diabetes, flash glucose monitoring, Venous blood glucose

    Received: 22 Jan 2024; Accepted: 02 May 2024.

    Copyright: © 2024 Ge, Zhang, Wang, 李, Su, Ding and Ma. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Dafa Ding, Department of Endocrinology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China, Nanjing, China
    Jianhua Ma, Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University,, Nanjing, Liaoning Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.